Ad is loading...
FIDFX
Price
$35.15
Change
+$0.41 (+1.18%)
Updated
Nov 22 closing price
JVMIX
Price
$32.25
Change
+$0.32 (+1.00%)
Updated
Nov 22 closing price
Ad is loading...

FIDFX vs JVMIX

Header iconFIDFX vs JVMIX Comparison
Open Charts FIDFX vs JVMIXBanner chart's image
Fidelity Advisor Mid Cap Value Z
Price$35.15
Change+$0.41 (+1.18%)
VolumeN/A
CapitalizationN/A
JHancock Disciplined Value Mid Cap I
Price$32.25
Change+$0.32 (+1.00%)
VolumeN/A
CapitalizationN/A
FIDFX vs JVMIX Comparison Chart
Loading...
View a ticker or compare two or three
VS
FIDFX vs. JVMIX commentary
Nov 23, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FIDFX is a Buy and JVMIX is a Buy.

FUNDAMENTALS
Fundamentals
JVMIX has more cash in the bank: 24.2B vs. FIDFX (1.91B). JVMIX (0.84) and FIDFX (0.82) have matching dividends . FIDFX was incepted earlier than JVMIX: FIDFX (8 years) vs JVMIX (27 years). FIDFX is a more actively managed with annual turnover of: 78.00 vs. JVMIX (41.00). FIDFX has a lower initial minimum investment than JVMIX: FIDFX (0) vs JVMIX (250000). FIDFX annual gain was more profitable for investors over the last year : 33.60 vs. JVMIX (22.12). FIDFX return over 5 years is better than : 64.78 vs. JVMIX (48.14).
FIDFXJVMIXFIDFX / JVMIX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence8 years27 years-
Gain YTD20.75116.661125%
Front LoadN/AN/A-
Min. Initial Investment0250000-
Min. Initial Investment IRAN/AN/A-
Net Assets1.91B24.2B8%
Annual Yield % from dividends0.820.8497%
Returns for 1 year33.6022.12152%
Returns for 3 years20.8311.06188%
Returns for 5 years64.7848.14135%
Returns for 10 yearsN/A63.69-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SRI6.410.32
+5.25%
Stoneridge
UK1.220.04
+3.39%
Ucommune International Ltd
BOWL11.830.26
+2.25%
Bowlero Corp
RHI73.701.09
+1.50%
Robert Half
RGLS1.40N/A
N/A
Regulus Therapeutics